Theravance Biopharma (TBPH) Return on Sales (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales rose 1.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 2.0% increase from a year earlier, with the FY2025 full-year figure at 0.1%, up 11.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, down from 0.01% in the prior quarter.
• Over the last five years, Return on Sales for TBPH reached as high as 0.74% in Q3 2022 and fell as low as 0.02% in Q1 2023.
• Historically, Return on Sales has averaged 0.04% across 5 years, with a median of 0.0% in 2023.
• Across the five-year window, Return on Sales jumped 73 bps in 2022 and slumped 75 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then plunged by 214 bps to 0.0% in 2023, then sank by 174 bps to 0.01% in 2024, then jumped by 175 bps to 0.01% in 2025, then sank by 145 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.